Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Platelet activation factor antagonists

D8. DeJoy, S. Q., Jeyaseelan, R., Torley, L. W., Pickett, W. C., Wissner, A., Wick, M. M., Oronsky, A. L., and Kerwar, S. S., Effect of CL 184,005, a platelet-activating factor antagonist in a murine model of Staphylococcus aureus-induced gram-positive sepsis. J. Infect. Dis. 169, 150-156... [Pg.112]

D22. Dirkes, K., Harris, B. H., Connolly, R. J., Schwaitzberg, S. D., Dinarello, C. A., and Gelfand, J. A., Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia. 7. Pediatr. Surg. 29, 1055-1057 (1994). [Pg.113]

K10. Klabunde, R. E., and Calvello, C., Inhibition of endotoxin-induced microvascular leakage by a platelet-activating factor antagonist and 5-lipoxygenase inhibitor. Shock 4, 368-372 (1995). [Pg.119]

Panetta, T., MarcheselH, V. L., Braquet, P., Spinnewyn, B. and Bazan, N. G. Effects of a platelet-activating factor antagonist (BN52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain Inhibition of ischemia-reperfusion induced cerebral injury. Biochem. Biophys. Res. Commun. 149 580-587,1987. [Pg.589]

The replacement of the polar head group of a range of piperazines by a 2-methylimidazo[4,5-f]pyridine group provided efficient orally active platelet-activating factor antagonists, for example, compounds 191-193 <1996JME487>. [Pg.483]

A platelet-activating factor, l-0-alkyl-2-(R)acetyl-sn-glyceryl-3-phosphocholine, is released in the presence of shock and ischemia. The platelet-activating factor antagonist can protect the heart and brain against ischemic injury. [Pg.42]

J3. Johnson, C. D., Kingsnorth, A. N., Imrie, C. W., McMahon, M. J., Neoptolemos, J. P., McKay, C., Toh, S. K., Skaife, P., Leeder, P. C., Wilson, P., Larvin, M., and Curtis, L. D., Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, Lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 48, 62-69... [Pg.75]

Other platelet-activating factor antagonists consisting of 1,4-dihydropyridine derivatives, (III), were prepared by the authors (3) and used in treating neurological diseases. [Pg.408]

Braquet, P. The ginkgolides potent platelet-activating factor antagonists isolated from Ginkgo biloba L. chemistry, pharmacology and clinical applications. Drugs Future, 1987, 12 643-699. [Pg.319]

Prehn, J. H. Krieglstein, J. Platelet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick telencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo. J. Neurosci. Res., 1993, 34 179-188. [Pg.323]

Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG (1999) Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 53 391-396. [Pg.620]

Kawaguchi A, Sugimoto K, Fujimura A. Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity. Life Sci 2001 68 1181-1190. [Pg.659]

Burstein, S. Platelet Activating Factor Antagonist and Methods of Use Therefor 1990 US 4,973,603... [Pg.178]

Summers. J.B. etal. (1995) Platelet activating factor antagonists. Adv. Pharmacol.. 32.67-168. [Pg.226]

See other pages where Platelet activation factor antagonists is mentioned: [Pg.120]    [Pg.301]    [Pg.590]    [Pg.548]    [Pg.73]    [Pg.85]    [Pg.437]    [Pg.79]    [Pg.691]    [Pg.149]    [Pg.223]    [Pg.403]    [Pg.408]    [Pg.460]    [Pg.461]    [Pg.463]    [Pg.230]    [Pg.659]    [Pg.326]    [Pg.301]    [Pg.95]    [Pg.49]    [Pg.95]    [Pg.95]    [Pg.68]    [Pg.283]   


SEARCH



Active factors

Activity factor

Platelet activation factor

Platelet-activating factor antagonist

Platelets activation

© 2024 chempedia.info